Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason E Stout

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
Biorxiv : the Preprint Server for Biology|December 23, 2024
Humoral correlate of vaccine-mediated protection from tuberculosis identified in humans and non-human primatesNatasha S Kelkar, Nicholas C Curtis, Timothy P Lahey, et al.
The European Respiratory Journal|February 5, 2021
Optimising pyrazinamide for the treatment of tuberculosisNan Zhang, Radojka M Savic, Martin J Boeree, et al.
Journal of Clinical Microbiology|October 27, 2021
Genomic Analysis of a Hospital-Associated Outbreak of Mycobacterium abscessus: Implications on TransmissionRebecca M Davidson, Sophie E Nick, Sara M Kammlade, et al.
Mbio|August 7, 2025
Paired single-cell and spatial transcriptional profiling reveals a central osteopontin macrophage response mediating tuberculous granuloma formationCharlie J Pyle, Liuyang Wang, Rebecca W Beerman, et al.
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trialSusan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
Immunity|October 21, 2016
Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes InfectionMark R Cronan, Rebecca W Beerman, Allison F Rosenberg, et al.
Cell|November 10, 2022
An ancestral mycobacterial effector promotes dissemination of infectionJoseph W Saelens, Mollie I Sweeney, Gopinath Viswanathan, et al.
BMC Infectious Diseases|February 21, 2014
A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern TanzaniaElizabeth A Reddy, Boniface N Njau, Susan C Morpeth, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 7, 2020
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineCharles L Daley, Jonathan M Iaccarino, Christoph Lange, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Biorxiv : the Preprint Server for Biology|December 23, 2024
Humoral correlate of vaccine-mediated protection from tuberculosis identified in humans and non-human primatesNatasha S Kelkar, Nicholas C Curtis, Timothy P Lahey, et al.
The European Respiratory Journal|February 5, 2021
Optimising pyrazinamide for the treatment of tuberculosisNan Zhang, Radojka M Savic, Martin J Boeree, et al.
Journal of Clinical Microbiology|October 27, 2021
Genomic Analysis of a Hospital-Associated Outbreak of Mycobacterium abscessus: Implications on TransmissionRebecca M Davidson, Sophie E Nick, Sara M Kammlade, et al.
Mbio|August 7, 2025
Paired single-cell and spatial transcriptional profiling reveals a central osteopontin macrophage response mediating tuberculous granuloma formationCharlie J Pyle, Liuyang Wang, Rebecca W Beerman, et al.
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trialSusan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
Immunity|October 21, 2016
Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes InfectionMark R Cronan, Rebecca W Beerman, Allison F Rosenberg, et al.
Cell|November 10, 2022
An ancestral mycobacterial effector promotes dissemination of infectionJoseph W Saelens, Mollie I Sweeney, Gopinath Viswanathan, et al.
BMC Infectious Diseases|February 21, 2014
A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern TanzaniaElizabeth A Reddy, Boniface N Njau, Susan C Morpeth, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 7, 2020
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineCharles L Daley, Jonathan M Iaccarino, Christoph Lange, et al.
Pageof 14